TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02703272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Participants will receive a cumulative dose of vincristine 1.6 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Participants will receive a cumulative dose of idarubicin 20 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Participants will receive a cumulative dose of idarubicin 20 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive a cumulative dose of dexamethasone 100 mg/m\^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive a cumulative dose of dexamethasone 100 mg/m\^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.
Study: NCT03096678

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Imaging
Description: Using a comprehensive MR study (Function, LGE, Tissue Characterization, Strain, T1/T2 mapping) to predict the outcome of LBBB with different cardiac function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Imaging
Description: Using a comprehensive MR study (Function, LGE, Tissue Characterization, Strain, T1/T2 mapping) to predict the outcome of LBBB with different cardiac function.
Study: NCT04116827

Intervention type: DRUG
Intervention: Tamoxifen Oral Tablet
Description: Patients who are scheduled for application of tamoxifen and goserelin
Study: NCT04236518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diets with either predominantly animal protein sources.
Description: 20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from animal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diets with predominantly plant protein sources
Description: 20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from vegetal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
Study: NCT03185715

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Oral and written counselling
Description: Recipients were informed about success rates of SET and DET and also about the possible risks of DET. All the information was given orally and written.
Study: NCT01921192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid, vit B6 and B12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01283334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
Study: NCT03136458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Description: Repeated remote ischemic preconditioning by arterial cuff insufflation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous normal saline
Description: endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endovenous normal saline
Description: endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.
Study: NCT01775982

Intervention type: OTHER
Intervention: Psychiatric evaluation
Description: This evaluation is carried out in several stages:~* Assessment of cognitive functioning;~* Interview with a relative;~* Interview with caregivers;~* Evaluation of the presence of delirium according to DSM-IV criteria;~* Evaluation of the presence of anxiety, depressive syndrome, dementia or other DSM IV;~* Reports of adverse events.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment.

Intervention type: OTHER
Intervention: Geriatric evaluation
Description: This evaluation includes a brief interview with a caregiver, diverse scorings (CAM, Delirium Index, Mini Geriatric Depression Scale, Modified Early Warning Score, Clinical Global Impression sclae, Algo Plus), and adverse event reporting.~CAM scoring is carried out by a trained geriatrician and a trained nurse and/or a psychologist.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment.
Study: NCT04091100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: An electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes. All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release
Description: longitudinal stretching, friction massage and pinching technique, All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
Study: NCT04888442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pCAR-19B cells
Description: Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT01898221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a \~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.
Study: NCT00032188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01056198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Santyl
Description: 2 mm Santyl applied once daily.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Daily gauze and optional sharp debridement
Study: NCT00776113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg tablets
Description: bioequivalence Carvedilol fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 12.5 mg tablets
Description: bioequivalence Carvedilol fasting
Study: NCT00905281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Group
Description: On inclusion, a visit will be organized between the patient and at least 2 members of the DISSPO staff. It will allow an evaluation of supportive care needs and the proposition of a personalized care plan.~Then, a consultation between the referring oncologist and the DISSPO will be organized once a month, so that the personalized care plan could be adapted if necessary.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: No specific intervention
Study: NCT01232881

Intervention type: PROCEDURE
Intervention: Tumor Sample
Description: Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.

Intervention type: PROCEDURE
Intervention: Serum Sample
Description: Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
Study: NCT02977611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Iron sucrose will be infused at dose of 500 mg over a one hour period
Study: NCT04217837

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulator
Description: Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.
Study: NCT04190498

Intervention type: DIAGNOSTIC_TEST
Intervention: Nocturnal oximetry
Description: Diagnosis of OSA will be based on the 3% Oxygen Desaturation Index (IDO) obtained by home nocturnal oximetry. The oximetry recordings will be centralized in sleep laboratory of the University Hospital of Grenoble Alpes. Oximetry data will be analyzed by a technician from the sleep laboratory of the University Hospital of Grenoble Alpes

Intervention type: DIAGNOSTIC_TEST
Intervention: Nocturnal oximetry
Description: Diagnosis of OSA will be based on the 3% Oxygen Desaturation Index (IDO) obtained by home nocturnal oximetry. The oximetry recordings will be centralized in sleep laboratory of the University Hospital of Grenoble Alpes. Oximetry data will be analyzed by a technician from the sleep laboratory of the University Hospital of Grenoble Alpes
Study: NCT03319264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamometry exam
Description: Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking test
Description: A 4 metres walking test will be performed to assess patient's walking speed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DXA measurement
Description: DXA measurement will be performed to assess patient's body composition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SARQOL questionnaire
Description: Patient's quality of life will be assessed thanks to the SARQOL questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life habits Questionnaire
Description: Life habits Questionnaire
Study: NCT00824382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL 2 Âµg
Description: 2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL 5 Âµg
Description: 2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL 10 Âµg
Description: 2 puffs of 5 Âµg/actuation delivered by RespimatÂ®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 puffs delivered by the RespimatÂ® inhaler
Study: NCT04376125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital inhibition in tension headache
Description: Deep maneuver of myofascial induction in the suboccipital muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suboccipital inhibition in tension headache
Description: Deep maneuver of myofascial induction in the suboccipital muscles
Study: NCT04649736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory and psychological rehabilitation
Description: Respiratory rehabilitation consists of 12 sessions of respiratory and physical exercises that patients perform at home with the help of a physiotherapist. Sessions have 1 hour of duration and are performing twice a week. Exercises include (1) Training of the respiratory muscles through pursed-lip breaths. (2) Effective cough exercises. (3) Diaphragmatic contractions in a supine position with a lightweight placed on the anterior abdominal wall. (4) Stretching exercise of extremities and the back.~The psychological support consists of 1 session to make the psychological history of the participant, and 6 sessions of emotion-centered problem-solving therapy, with cognitive-behavioral components and psychological management of emergencies and crises. These sessions have a 1-hour duration and are telephone-provided once a week by psychologists following the guidelines of the Inter-Agency Standing Committee on Mental Health and Psychosocial Support in Humanitarian and Disaster Emergencies.
Study: NCT03277053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control.
Description: Patient receive an ipad with no application.
Study: NCT01532336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVC-422 Solution, 0.3%
Description: NVC-422 Ophthalmic Solution dropped onto the eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVC-422 Vehicle Solution
Description: NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
Study: NCT02455258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance/Movement Therapy (DMT)
Description: Each DMT session follows a similar structure of Opening, Warm up, Development, Cool Down and Closure. Various themes dedicated to an aging population are addressed by the supervising dance/movement therapist through movement activities and using support material (i.e., props, music). This group is provided in a group setting of maximum 10 participants at a time and occurs 3 times per week for 1 hour each session over the course of 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobics Exercise (AE)
Description: The aerobics exercise program is composed of warm up exercises followed by cardiovascular training on a recumbent bicycle. The intensity is set and progressively increased using each participants' individualized maximal aerobic power obtained in the baseline VO2 evaluation. This program respects the recommendations made by the American College of Sports Medicine and their adaptations for aging populations. Each session is supervised by a kinesiologist with 2 participants at a time. The training occurs 3 times per week for 1 hour each session over the course of 12 weeks.
Study: NCT00129727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given intravenously
Study: NCT03009877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC Premium Video Intubation Platform-KARL STORZ
Description: After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
Study: NCT00129727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously
Study: NCT00858312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high dairy diet
Description: 12 week energy restriction with 3-4 servings of dairy foods/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Dairy
Description: less than 1 serving of dairy foods per day.
Study: NCT00940966

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard ADA diet
Description: standard ADA diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: energy restricted very-low carbohydrate diet
Description: energy restricted very-low carbohydrate diet
Study: NCT03009877

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC Premium Video Intubation Platform-KARL STORZ
Description: After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
Study: NCT03857516

Intervention type: DEVICE
Intervention: Multipolar left ventricular lead implantation
Description: Multipolar left ventricular lead implantation with measurements of pacing thresholds in varrious pacing configurations.
Study: NCT00940966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: energy restricted very-low carbohydrate diet
Description: energy restricted very-low carbohydrate diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low glycemic diet
Description: restricted ketogenic diet
Study: NCT03580434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-STRUT
Description: Minimally invasive implantation of V-STRUT
Study: NCT03748576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telemedicine: management through WeChat group chat
Description: Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care
Study: NCT04015596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium
Description: Dosed by weight (10mg/kg), twice daily, for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants take placebo pills twice daily, for 8 weeks.
Study: NCT00864825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
Study: NCT00124202

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: a fatty meal
Description: Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
Study: NCT02822573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil 5 mg
Description: Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
Study: NCT01946893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: A standardized and structured program based on Mindfulness Based Cognitive Therapy and Mindfulness Based Stress Reduction and has been piloted in our laboratory.Each session included 1) discussion on stress, relaxation, meditation, and mind-body interaction, 2) instruction and practice in formal and informal MM, and 3) enquiry about problem-solving techniques regarding success and difficulty in practicing mindfulness. Formal meditation instruction included a mindful Body Scan and Sitting Meditation (awareness of breath, body sensations, cognitive and emotional processes). Informal practice of mindful daily activities (e.g., washing dishes) was also taught to generalize mindfulness beyond the formal meditations. A 3-minute meditation was offered as a quick coping strategy, and it could be practiced with or without a guided recording.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The Education control was matched for session time and home practice. The internet sessions included a general health video and questions about the material. For home practice, the participants listened to podcasts about the same topic. The session topics were 1) Healthy Eating, 2) Healthy Exercise, 3) Healthy Sleep, 4) Healthy Brain, 5) Healthy Mood, and 6) Community Involvement.
Study: NCT03756727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Patients in Ascorbic acid group received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery (once a day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in Control Comparator group received saline 10ml at the night before surgery, during the surgery and five days after surgery (once a day).
Study: NCT00003134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT02054598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid and navigation
Description: Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.